newsfilter
← Latest News
Business Wire·

Belharra Therapeutics Debuts With $130 Million in Funding

--Next-generation chemoproteomics company launched by Versant Ventures' Inception Discovery Engine with ability to target any binding site, on any protein, in any cell type-- --Emerges from stealth with a $50 million